Published in J Natl Cancer Inst on February 22, 2014
Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men: a randomized clinical trial. Cancer Prev Res (Phila) (2014) 1.57
Selenium supplementation and prostate cancer mortality. J Natl Cancer Inst (2014) 1.44
Is the inverse association between selenium and bladder cancer due to confounding by smoking? Am J Epidemiol (2015) 1.39
Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Med (2015) 0.98
Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. Sci Transl Med (2015) 0.92
Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence. Oncotarget (2016) 0.86
Molecular cancer prevention: Current status and future directions. CA Cancer J Clin (2015) 0.86
Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature. Nutrients (2016) 0.85
Selenium and chronic diseases: a nutritional genomics perspective. Nutrients (2015) 0.84
The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. Nutrients (2014) 0.83
Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence. Prostate (2014) 0.82
Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods. Asian J Androl (2015) 0.81
Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges. Nutr Cancer (2015) 0.79
Induction of ROS Overload by Alantolactone Prompts Oxidative DNA Damage and Apoptosis in Colorectal Cancer Cells. Int J Mol Sci (2016) 0.78
Status and Interrelationship of Zinc, Copper, Iron, Calcium and Selenium in Prostate Cancer. Indian J Clin Biochem (2015) 0.78
New concepts and challenges in the clinical translation of cancer preventive therapies: the role of pharmacodynamic biomarkers. Ecancermedicalscience (2015) 0.78
Coenzyme Q10 and α-tocopherol reversed age-associated functional impairments in mice. Exp Gerontol (2014) 0.78
Micronutrients in Oncological Intervention. Nutrients (2016) 0.77
Serum tocopherol levels and vitamin E intake are associated with lung function in the normative aging study. Clin Nutr (2015) 0.77
A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res (Phila) (2014) 0.77
Intake of vitamins A, C, and E and folate and the risk of ovarian cancer in a pooled analysis of 10 cohort studies. Cancer Causes Control (2015) 0.76
Lessons learned from cancer prevention studies with nutrients and non-nutritive dietary constituents. Mol Nutr Food Res (2016) 0.76
A Perspective on Prostate Carcinogenesis and Chemoprevention. Curr Pharmacol Rep (2015) 0.76
Is There a Future for Chemoprevention of Prostate Cancer? Cancer Prev Res (Phila) (2016) 0.75
Baseline selenium and prostate cancer risk: comments and open questions. J Natl Cancer Inst (2014) 0.75
Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Yeast as a model system to study metabolic impact of selenium compounds. Microb Cell (2015) 0.75
Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies. J Natl Cancer Inst (2016) 0.75
Prostate cancer: new data on risks of selenium and vitamin E. Nat Rev Urol (2014) 0.75
JNCI and cancer prevention. J Natl Cancer Inst (2015) 0.75
Multilevel modeling and value of information in clinical trial decision support. BMC Syst Biol (2014) 0.75
Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Semin Oncol (2015) 0.75
Prevention of prostate cancer: outcomes of clinical trials and future opportunities. Am Soc Clin Oncol Educ Book (2014) 0.75
Biosynthesis of Se-methyl-seleno-l-cysteine in Basidiomycetes fungus Lentinula edodes (Berk.) Pegler. Springerplus (2016) 0.75
A Nutritional Approach to the Prevention of Cancer: from Assessment to Personalized Intervention. Transl Med UniSa (2016) 0.75
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Breast Cancer Res Treat (2016) 0.75
Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men. Oncotarget (2017) 0.75
A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate. Oncotarget (2017) 0.75
Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences. Oncotarget (2017) 0.75
Vitamin K and its analogs: Potential avenues for prostate cancer management. Oncotarget (2017) 0.75
Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer Prevention. Cancer Prev Res (Phila) (2016) 0.75
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med (1994) 16.96
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Histologic grading of prostate cancer: a perspective. Hum Pathol (1992) 3.36
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst (1998) 2.97
Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst (2000) 2.77
Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst (2006) 2.48
Selenium for preventing cancer. Cochrane Database Syst Rev (2011) 2.11
Vitamin E supplements and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev (2004) 1.72
Use of selenium concentration in whole blood, serum, toenails, or urine as a surrogate measure of selenium intake. Epidemiology (1996) 1.40
Selenium and prostate cancer: systematic review and meta-analysis. Am J Clin Nutr (2012) 1.32
Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer (2006) 1.31
Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Control (2005) 1.27
Predictors of selenium concentration in human toenails. Am J Epidemiol (1990) 1.23
Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control (2007) 1.22
Lessons learned from randomized clinical trials of micronutrient supplementation for cancer prevention. Annu Rev Nutr (2012) 1.07
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control (2001) 1.04
Advanced prostate cancer risk in relation to toenail selenium levels. J Natl Cancer Inst (2013) 1.00
Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res (1999) 0.94
Toenail trace element levels and breast cancer: a prospective study. Am J Epidemiol (1996) 0.94
Selenium in diet, blood, and toenails in relation to human health in a seleniferous area. Am J Clin Nutr (1991) 0.94
Selenium and prostate cancer: the puzzle isn't finished yet. Am J Clin Nutr (2012) 0.92
Synergistic effect of vitamin E and selenium in the chemoprevention of mammary carcinogenesis in rats. Cancer Res (1983) 0.85
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Lung cancer. N Engl J Med (2008) 13.49
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med (2013) 7.53
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA (2013) 5.56
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci U S A (2007) 4.77
Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer (2004) 4.70
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
Reactive oxygen species: a breath of life or death? Clin Cancer Res (2007) 4.20
Statins and cancer prevention. Nat Rev Cancer (2005) 4.12
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol (2012) 3.65
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst (2006) 3.63
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med (2012) 3.52
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48